Literature DB >> 2208796

Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins.

G Dighiero1, P Lymberi, C Monot, N Abuaf.   

Abstract

Using ELISA methods, 54 sera from chronic active hepatitis (CAH) patients displaying high levels of anti-smooth muscle antibodies (SMA) and 18 sera from primary biliary cirrhosis (PBC) patients with high levels of anti-M2 antibodies were examined for the presence of high antibody levels against actin, tubulin, myosin, tropomyosin, troponin, vimentin and desmin. Our results showed that: (i) in CAH with high SMA activity, increased antibody levels were found in 51.9% of sera for actin, 31.5% for myosin, 35.2% for tubulin, 34.0% for tropomyosin, 11.3% for troponin, 22.6% for vimentin and 43.4% for desmin, compared with natural antibody levels in 21 normal sera; (ii) Similar high levels of these antibodies were found in the case of PBC; (iii) in most cases, sera simultaneously bound to several antigens of the panel; and (iv) approximately 26% of the CAH sera were found to be negative with the seven antigens examined while 22% were reacted with a cytoskeleton protein (CP) other than actin. These results indicate that current opinion associating SMA with anti-actin activity in CAH is confirmed for only 50% of cases and that although a good correlation between SMA and anti-CP antibodies can be obtained, there is still a significant percentage of SMA for which the putative antigen recognized needs to be determined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208796      PMCID: PMC1535166          DOI: 10.1111/j.1365-2249.1990.tb05402.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Human smooth muscle autoantibodies reacting with intermediate (100 A) filaments.

Authors:  P Kurki; E Linder; I Virtanen; S Stenman
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

2.  Smooth muscle antibodies of actin and "non-actin" specificity.

Authors:  P Kurki; E Linder; A Miettinen; O Alfthan
Journal:  Clin Immunol Immunopathol       Date:  1978-04

3.  Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells.

Authors:  S Whittingham; I R Mackay; J Irwin
Journal:  Lancet       Date:  1966-06-18       Impact factor: 79.321

4.  The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin.

Authors:  J A Spudich; S Watt
Journal:  J Biol Chem       Date:  1971-08-10       Impact factor: 5.157

5.  Microtubule assembly in the absence of added nucleotides.

Authors:  M L Shelanski; F Gaskin; C R Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

6.  Antibody to smooth muscle in patients with liver disease.

Authors:  G D Johnson; E J Holborow; L E Glynn
Journal:  Lancet       Date:  1965-10-30       Impact factor: 79.321

7.  Classification of smooth muscle autoantibodies detected by immunofluorescence.

Authors:  G F Bottazzo; A Florin-Christensen; A Fairfax; G Swana; D Doniach; U Groeschel-Stewart
Journal:  J Clin Pathol       Date:  1976-05       Impact factor: 3.411

8.  Myosin autoantibodies detected by immunofluorescence.

Authors:  A J Fairfax; U Gröschel-Stewart
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

9.  Smooth muscle autoantibodies in infectious mononucleosis.

Authors:  E J Holborow; E H Hemsted; S V Mead
Journal:  Br Med J       Date:  1973-08-11

10.  Human smooth muscle autoantibody. Its identification as antiactin antibody and a study of its binding to "nonmuscular" cells.

Authors:  G Gabbiani; G B Ryan; J P Lamelin; P Vassalli; G Majno; C A Bouvier; A Cruchaud; E F Lüscher
Journal:  Am J Pathol       Date:  1973-09       Impact factor: 4.307

View more
  9 in total

1.  Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA.

Authors:  A Zamanou; A Tsirogianni; C Terzoglou; A Balafas; I Economidou; P Lymberi
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Alpha tropomyosin as a self-antigen in patients with Behçet's disease.

Authors:  S P Mahesh; Zhuqing Li; R Buggage; F Mor; I R Cohen; E Y Chew; R B Nussenblatt
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

3.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

4.  IgG from patients with liver diseases inhibit mitochondrial respiration in permeabilized oxidative muscle cells: impaired function of intracellular energetic units?

Authors:  Lumme Kadaja; Kai E Kisand; Nadezhda Peet; Urmo Braun; Kaja Metsküla; Kaupo Teesalu; Riina Vibo; Kalle V Kisand; Raivo Uibo; Harald Jockusch; Enn K Seppet
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

Review 5.  Anti-cardiac troponin antibodies in clinical human disease: a systematic review.

Authors:  Eduardo M Vilela; Rita Bettencourt-Silva; J Torres da Costa; Ana Raquel Barbosa; Marisa P Silva; Madalena Teixeira; João Primo; Vasco Gama Ribeiro; José Pedro L Nunes
Journal:  Ann Transl Med       Date:  2017-08

6.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

7.  Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis.

Authors:  Troy D Jaskowski; Eric Q Konnick; Edward R Ashwood; Christine M Litwin; Harry R Hill
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

8.  Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis.

Authors:  A J Czaja; K D Pfeifer; R H Decker; A S Vallari
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

Review 9.  To screen or not to screen? Celiac antibodies in liver diseases.

Authors:  Janaína Luz Narciso-Schiavon; Leonardo Lucca Schiavon
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.